Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 83 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s00280-019-03810-9
  • Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1195-1196
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.